ArticleFacts, views & vision in ObGyn2018
HPV vaccination coverage in the federal state of Belgium according to regions and their impact.
Article in Facts, views & vision in ObGyn, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The Cervical Cancer Paradox in Eastern Europe: How Knowledge and Institutional Trust Shape HPV Vaccination Attitudes in Romania.Medical sciences (Basel, Switzerland) · 2026Observational
- Clinical guidance paper VVOG HPV vaccination in women undergoing conisation for CIN2 + lesions to prevent recurrence.European journal of obstetrics & gynecology and reproductive biology: X · 2025Article
- The distribution and the relationship of HPV subtypes infection with pregnancy outcomes.Scientific reports · 2025Article
- Sexually transmitted infections in Belgian general practices: a nationwide continuing surveillance study, data from 2015 to 2020.Primary health care research & development · 2024Article
- Policy brief Belgian EBCP mirror group 'prevention' and 'early detection & screening' in cancer.Archives of public health = Archives belges de sante publique · 2024Article
- Epidemiology, Molecular Pathogenesis, Immuno-Pathogenesis, Immune Escape Mechanisms and Vaccine Evaluation for HPV-Associated Carcinogenesis.Pathogens (Basel, Switzerland) · 2023Review
- Challenges and opportunities to making Indian women cervical cancer free.The Indian journal of medical research · 2023Article
- Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective.Frontiers in immunology · 2023Review
- Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (July-December 2020).Vaccine · 2022Article
- Article
- Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.Frontiers in pharmacology · 2021Article
- Progress in Vaccination of Prophylactic Human Papillomavirus Vaccine.Frontiers in immunology · 2020Review
- HPV negative cervical cancers and primary HPV screening.Facts, views & vision in ObGyn · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term results of the HPV vaccination programs in Australia and Scotland have shown a tremendous impact on the reduction of HPV infection rates and precancerous diseases. Both countries started mass vaccination ten years (Australia) and eight years (Scotland) ago and achieved a vaccination coverage of more than 80 %. Within 20 to 30 years a reduction in cervical cancer by more than 75 % is expected. Furthermore, there will be a reduction in other HPV related cancers like vaginal, vulva, perineal, anal and oropharyngeal cancers. In order to be successful, a high vaccination coverage is needed. In Belgium, the vaccination was introduced in 2010 in the Flemish community and in 2011 in the French community. In the first vaccinated cohorts the coverage in Flemish and French Communities was respectively 84% (2010) and 29% (2012-2013). The latest data suggest that the Flemish Community (Flanders Region) attained a coverage of 91 % while the French Community (Walloon Region) attained a coverage of around 36 %. The regional difference in coverage offers a real-life case. The worst-case scenario could end up with proportionally one half of country having more HPV related cancers than the other half. Currently efforts are performed to increase the coverage rates in both regions and consequently decreasing this difference. Additionally, the updated recommendations regarding the HPV vaccination by the Belgian NITAG (National Immunization Technical Advisory Group) stated that the HPV vaccination should be gender neutral. This could stimulate the vaccination program and increase the coverage. The coverage rate in Flanders is among the highest in the world and the rate in the French Community is increasing. Efforts should be continued in order to maintain trust and increase the coverage rate.
Indexed as
Identifiers
31110649PMC6516187What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.